Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Reduced antigenicity – reduced ability to bind complement – or...
Reexamination Certificate
2007-12-13
2010-02-16
Schwadron, Ron (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reduced antigenicity, reduced ability to bind complement, or...
C514S002600, C514S013800, C514S885000, C530S326000
Reexamination Certificate
active
07662386
ABSTRACT:
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
REFERENCES:
patent: 5350840 (1994-09-01), Call et al.
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5633142 (1997-05-01), Herlyn et al.
patent: 5670317 (1997-09-01), Ladanyi et al.
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5726288 (1998-03-01), Call et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6096313 (2000-08-01), Jager et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6316599 (2001-11-01), Call et al.
patent: 6818751 (2004-11-01), Xu et al.
patent: 7063854 (2006-06-01), Gaiger et al.
patent: 7115272 (2006-10-01), Gaiger et al.
patent: 7144581 (2006-12-01), Gaiger et al.
patent: 7316924 (2008-01-01), Bron et al.
patent: 7329410 (2008-02-01), Gaiger et al.
patent: 2003/0039635 (2003-02-01), Gaiger et al.
patent: 2003/0072767 (2003-04-01), Gaiger et al.
patent: 1004319 (2000-05-01), None
patent: 1103564 (2001-05-01), None
patent: 11-89596 (1999-04-01), None
patent: 11-89599 (1999-04-01), None
patent: WO 91/07509 (1991-05-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO95/06725 (1995-03-01), None
patent: WO95/29995 (1995-11-01), None
patent: WO 96/38176 (1996-12-01), None
patent: WO 99/03506 (1999-01-01), None
patent: WO99/58135 (1999-11-01), None
patent: WO 00/06602 (2000-02-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 00/26249 (2000-05-01), None
patent: WO 0125273 (2001-04-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/062920 (2001-08-01), None
patent: WO 01/72786 (2001-10-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/28414 (2002-04-01), None
patent: WO 03/037060 (2003-05-01), None
Aaronson and Todaro, “Development of 3t3-like lines from Balb/c mouse embryo cultures: transformation susceptibility to SV40,”J. Cell. Physiol. 72(2):141-148, Oct. 1968.
Adachi et al., “Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1),”Oncogene 13: 2197-2203, 1996.
Algar et al., “A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines,”Oncogene 12: 1005-1014, 1996.
Armstrong et al., “The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo,”Mechanisms of Development 40: 85-97, 1992.
Bellantuono et al., “Selective elimination of leukemic progenitors by allorestricted CTL specific for WILMS Tumor Antigen-1 (WT-1),”Blood, 94(10):532A-533A, Nov. 15, 1999.
Bergmann et al., “High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term Outcome,”Blood 90(3): 1217-1225, 1997.
Bergmann et al., “Wilms Tumor Gene Expression in Acute Myeloid Leukemias,”Leukemia and Lymphoma 25: 435-443, 1997.
Boon, T., “Tumor Antigens Recognized By Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy,”Int. J. Cancer 54: 177-180, 1993.
Brenner et al., “RNA polymerase chain reaction detects different levels of four alternatively splicedWT1transcripts in Wilms' tumors,”Oncogene 7: 1431-1433, 1992.
Brieger et al., “The Expression of the Wilms' Tumor Gene in Acute Myelocytic Leukemias as Possible Marker for Leukemic Blast Cells,”Leukemia 8(12): 2138-2143, 1994.
Brieger et al., “The Wilms' tumor gene is frequently expressed in acute myeloblastic leukemias and may provide a marker for residual blast cells detectable by PCR,”Annals of Oncology 6: 811-816, 1995.
Buckler et al., “Isolation, Characterization, and Expression of the Murine Wilms' Tumor Gene (WT1) During Kidney Development,”Molecular and Cellular Biology 11: 1707-1712, 1991.
Call et al., “Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome II Wilms' Tumor Locus,”Cell 60: 509-520, 1990.
Carapeti et al., “Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia,”Eur. J. Haematol. 58: 346-349, 1997.
Charles et al., “Expression of the Wilms' tumour gene WT1 in the developing human and in paediatric renal tumours: an immunohistochemical study,”J. Clin. Pathol: Mol. Pathol. 50: 138-144, 1997.
Charles et al., “Immunohistochemical detection of the Wilms' tumour gene WT1 in desmoplastic small round cell tumour,”Histopathology 30: 312-314, 1997.
Chen et al., “T-cells for tumor therapy can be obtained from antigen-loaded sponge implants,”Cancer Research 54(4):1065-1070, Feb. 15, 1994.
Chesebro et al., “Characterization of Ia8 antigen, THY-1.2 antigen, complemnt receptors, and virus production in a group of murine virus-induced leukemia cell lines,”The Journal of Immunology 117(4):1267-1274, Oct. 1976.
De Bruijn et al., “Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses,”Eur J Immunol 21(12):2963-2970, Dec. 1991.
Deavin et al., “Statistical comparison of established T-cell eptiope predictors against a large database of human and murine antigens,”Molecular Immunology, 33(2):145-155, 1996.
Drummond et al., “Repression of the Insulin-Like Growth Factor Gene by the Wilms Tumor Suppressor WT1,”Science 257: 674-677, 1992.
Feller and de la Cruz, “Tsites (Version 1.1) A computer program to determine T cell epitopes using four predictive algorithms,”Nature 349: 720-721, 1991.
Foster et al., “Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model,”Cancer Research 57(16):3325-3330, Aug. 15, 1997.
Frazier et al., “Expression of the Tumor Suppressor Gene WT1 in Both Human and Mouse Bone Marrow,”Blood 86: 4704-4706, 1995 (letter).
Gaiger et al., “Immunity to WT1 in animal models and leukemia pateints,”Blood, 94(10):78, Nov. 15, 1999.
Gaiger et al., “Immunity to WT1 in the animal model and in patients with acute myeloid leukemia,”Blood 96(4):1480-1489, Aug. 15, 2000.
Gaiger et al., “WT1: A new leukemia and cancer antigen A,”Proceedings of the Annual Meeting of the American Association for Cancer Research, 40:424, 1999.
Gillis and Smith, “Long term culture of tumour-specific cytotoxic T cells,”Nature 268:154-156, Jul. 14, 1977.
Glynn et al., “Cross-resistance to the transplantation of syngeneic friend, moloney, and rauscher virus-induced tumors,”Cancer Research 28(3):434-439, Mar. 1968.
Goodyer et al., “Repression of the retinoic acid receptor-α gene by the Wilms' tumor suppressor gene product, wt1,”Oncogene 10: 1125-1129, 1995.
Haber et al., “A dominant mutation in the Wilms tumor geneWT1cooperates with the viral oncogeneE1Ain transformation of primary kidney cells,”Proc. Natl. Acad. Sci. USA 89: 6010-6014, 1992.
Haber et al., “Alternative splicing and genomic structure of the Wilms tumor geneWT1,” Proc. Natl. Acad. Sci. USA 88: 9618-9622, 1991.
Haber et al., “An Internal Deletion within an 11p13 Zinc Finger Gene Contributes to the Development of Wilms' Tumor,”Cell 61: 1257-1269, 1990.
Hamilton et al., “High affinity binding sites for the Wilms' tumour suppressor protein WT1,”Nucleic Acids Research 23(2): 277-284, 1995.
Harrington et al., “Inhibition of Colony-stimulating Factor-1 Promoter Activity by the Product of the Wilms' Tumor Lo
Cheever Martin A.
Gaiger Alexander
Corixa Corporation
Schwadron Ron
Seed IP Law Group PLLC
University of Washington
LandOfFree
Compositions and methods for WT1 specific immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for WT1 specific immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for WT1 specific immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4163459